This study highlights the potential role of VCAM-1, a biomarker of inflammation and immune activation, as a prognostic indicator of impaired LV performance, as reflected by changes in left ventricular ejection fraction and left ventricular end-diastolic volume, following acute coronary syndromes. This evidence concerns the gene VCAM1 and acute coronary syndrome.